ROSGQ (Rosetta Genomics) Total Equity: $1.10 Mil (As of Jun. 2017)


What is Rosetta Genomics Total Equity?

Rosetta Genomics ROSGQ -99.00% Total Equity is $1.10 Mil as of Jun. 2017.

Rosetta Genomics's total equity for the quarter that ended in Jun. 2017 was $1.10 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Rosetta Genomics Total Equity Historical Data

* Premium members only.

The historical data trend for Rosetta Genomics's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rosetta Genomics Total Equity Chart

Rosetta Genomics Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 30.90 23.63 15.07 19.62 4.42

Rosetta Genomics Semi-Annual Data
Dec07 Jun08 Dec08 Jun09 Dec09 Jun10 Dec10 Jun11 Dec11 Jun12 Dec12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19.82 19.62 12.65 4.42 1.10

Rosetta Genomics Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Rosetta Genomics's Total Equity for the fiscal year that ended in Dec. 2016 is calculated as

Total Equity=Total Assets(Q: Dec. 2016 )-Total Liabilities(Q: Dec. 2016 )
=11.961-7.544
=4.42

Rosetta Genomics's Total Equity for the quarter that ended in Jun. 2017 is calculated as

Total Equity=Total Assets(Q: Jun. 2017 )-Total Liabilities(Q: Jun. 2017 )
=6.207-5.108
=1.10

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of $1.10 Mil mean?
Rosetta Genomics (ROSGQ) has a Total Equity of $1.10 Mil as of Jun. 2017. The total amount of equity as record on a company's balance sheet. View historical data for Rosetta Genomics and its competitors.
Is Rosetta Genomics' Total Equity too high?
Rosetta Genomics' current Total Equity is $1.10 Mil.
How does Rosetta Genomics' Total Equity compare to TEAR and IDTA?
Rosetta Genomics' Total Equity of $1.10 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Medical Diagnostics & Research company?
A good Total Equity depends on the Medical Diagnostics & Research industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Rosetta Genomics and its competitors. Rosetta Genomics's current Total Equity is $1.10 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rosetta Genomics stock overvalued right now?
Rosetta Genomics (ROSGQ) has a current Total Equity of $1.10 Mil. The current Total Equity is $1.10 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Rosetta Genomics (ROSGQ), the current Total Equity is $1.10 Mil as of Jun. 2017. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Rosetta Genomics Business Description

Address 10 Plaut Street, Science Park, Rehovot, ISR, 76706
Rosetta Genomics Ltd is an Israel based genomic diagnostics company operating globally. It is focused on research and development on diagnostics and therapeutics in the field of microRNAs. The firm markets and sells four diagnostic tests based on its microRNA technologies namely, RosettaGX Cancer Origin for the identification of the primary site of metastatic cancer, mi-LUNG, mi-KIDNEY which is a microRNA-based kidney tumor classification test for pathology samples and RosettaGx Reveal which is a microRNA-based assay for the diagnosis of indeterminate thyroid fine-needle aspirate samples. Its revenues include Clinical testing revenues and Licensing revenues, of which Clinical testing revenue is maximum. The group generates its revenues mainly from diagnosing patient tissue.